Incyte Corporation (INCY) Tax Rate: 22.70%
Is Incyte Corporation’s tax rate high or low?
Incyte Corporation's tax rate of 22.70% is 65% above its 5-year average of 13.79%, around the middle of its 5-year range (-66.29%–89.70%).
59.61% below its 12-month average of 56.20%.
INCY Tax Rate Chart
INCY Average Tax Rate Chart
INCY Current vs Average Tax Rate Chart
INCY Tax Rate Metrics
TAX RATE
22.70%
TAX RATE AVG TTM
56.20%
TAX RATE AVG 3Y
44.09%
TAX RATE AVG 5Y
13.79%
TAX RATE AVG 10Y
10.21%
TAX RATE AVG 15Y
8.89%
TAX RATE AVG 20Y
3.48%
CURRENT VS TTM AVG
-59.61%
CURRENT VS 3Y AVG
-48.52%
CURRENT VS 5Y AVG
+64.59%
CURRENT VS 10Y AVG
+122.39%
CURRENT VS 15Y AVG
+155.28%
CURRENT VS 20Y AVG
+552.92%
Incyte Corporation Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Incyte Corporation Tax Rate FAQ
- What is the tax rate for Incyte Corporation (INCY)?
- The tax rate for INCY stock is 22.70%.
- Is Incyte Corporation's tax rate high or low?
- Incyte Corporation's tax rate of 22.70% is 65% above its 5-year average of 13.79%, around the middle of its 5-year range (-66.29%–89.70%).
- What is the TTM average tax rate for Incyte Corporation (INCY)?
- The TTM average tax rate for INCY stock is 56.20%.
- What is the 3Y average tax rate for Incyte Corporation (INCY)?
- The 3Y average tax rate for INCY stock is 44.09%.
- What is the 5Y average tax rate for Incyte Corporation (INCY)?
- The 5Y average tax rate for INCY stock is 13.79%.
- What is the 10Y average tax rate for Incyte Corporation (INCY)?
- The 10Y average tax rate for INCY stock is 10.21%.
- What is the 15Y average tax rate for Incyte Corporation (INCY)?
- The 15Y average tax rate for INCY stock is 8.89%.
- What is the 20Y average tax rate for Incyte Corporation (INCY)?
- The 20Y average tax rate for INCY stock is 3.48%.
Incyte Corporation Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | 22.70% |
| 2024-12-31 | 89.70% |
| 2023-12-31 | 28.36% |
| 2022-12-31 | 35.62% |
| 2021-12-31 | -66.29% |
| 2020-12-31 | -27.34% |
| 2019-12-31 | 8.19% |
| 2018-12-31 | 5.08% |
| 2017-12-31 | -0.27% |
| 2016-12-31 | 2.96% |
| 2015-12-31 | 13.57% |
| 2014-12-31 | 0.14% |
| 2013-12-31 | -0.36% |
| 2012-12-31 | -0.39% |
| 2011-12-31 | 0.00% |
| 2010-12-31 | 0.00% |
| 2008-12-31 | 0.00% |
| 2007-12-31 | 0.00% |
| 2006-12-31 | 0.00% |
| 2005-12-31 | 0.53% |
| 2004-12-31 | -0.28% |
| 2003-12-31 | -0.21% |
| 2002-12-31 | -0.71% |
| 2001-12-31 | -0.50% |
| 2000-12-31 | -0.63% |
| 1999-12-31 | 2.90% |
| 1998-12-31 | 40.68% |
| 1997-12-31 | 6.76% |
Related Metrics
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury